

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/564,647	First Named Inventor: Phillip David Monk, et al
371 Filing Date: July 19, 2006	Attorney Docket No.: 102789-1P US
Examiner: Skelding, Zachary S.	Group Art Unit: 1644
Customer No.: 44992	Confirmation No.: 1467
Title: HUMAN ANTIBODY MOLECULES FOR IL-13	

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a PTO/SB/08a Form with a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

In addition, Applicant(s) wish to call to the Examiner's attention the following commonly-owned, co-pending patent application which is also cited on the PTO/SB/08a Form (see items 5 and 6 under non-patent literature documents).

- 1) U.S. Application Serial No. 10/891,972 Attorney Docket No. 102789-4 US, filed on July 15, 2004.
- 2) U.S. Application Serial No. 11/821,880 Attorney Docket No. 102789-2P US, filed on June 25, 2007.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. _____, referencing Attorney Docket No. _____, or
- ☐ (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee, AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. _____, referencing Attorney Docket No. _____, or

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due since this IDS is being filed before a first office action on the merits, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 102789-1P US.

Respectfully submitted,
/ Christine McCormack/

Name: Christine McCormack
Dated: June 23, 2009
Reg. No.: 61,331
Phone No.: 781-839-4693
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451